Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 06h03 HE
|
Fennec Pharmaceuticals Inc.
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement...
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
14 mai 2024 05h53 HE
|
ALLIANCE PROMOTION MICROBIOTE
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai...
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
14 mai 2024 05h53 HE
|
ALLIANCE PROMOTION MICROBIOTE
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 -...
MRSA Drugs Global Strategic Research Report 2024: Market to Reach $1.6 Billion by 2030 - Glycopeptides & Lipoglycopeptides to Account for $660 Million
13 mai 2024 09h55 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "MRSA Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global MRSA Drugs Market to Reach $1.6...
Lifestyle Drugs Global Strategic Business Report 2024
13 mai 2024 09h11 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Lifestyle Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Lifestyle Drugs Market to Reach...
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
09 mai 2024 14h51 HE
|
Lumos Pharma, Inc.
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
09 mai 2024 08h00 HE
|
Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
08 mai 2024 16h05 HE
|
Assembly Biosciences, Inc.
Clinical trial application clearances received for a Phase 1a/1b trial for ABI-5366 targeting recurrent genital herpes, and a Phase 1b trial for ABI-4334 in chronic HBV infection; both studies on...
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
07 mai 2024 18h15 HE
|
Fennec Pharmaceuticals Inc.
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
06 mai 2024 06h05 HE
|
MannKind
MANNKIND RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR CLOFAZIMINE INHALATION SUSPENSION FOR THE TREATMENT OF SERIOUS LUNG DISEASE